An overview and the mechanism of action of RGX-314 is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA) as well as the limitations of anti-VEGF therapy for neovascular AMD.
The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022.
Questions:
- What are the limitations of anti-VEGF therapy for neovascular AMD?
- What is RGX-314 and what is its mechanism of action?
Disclosures: Arshad Khanani is a consultant for Regenxbio and discloses grant/research Support from Regenxbio.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
